Friday, September 28, 2012

The Next Big Thing in Biotech: Hepatitis Drugs

Investment Commentary

The Next Big Thing in Biotech: Hepatitis Drugs

Adam Feuerstein, Sr. Columnist for TheStreet, says heptatitis drugs are the next big things to watch in biotech.
Fri 09/28/12 02:00 AM EST -- Adam Feuerstein & Gregg Greenberg

Gilead Begins Single Pill Hepatitis C Study for 2014 Approval

AASLD 2012: The Liver Meeting: 63rd Annual Meeting of the American Association for the Study of Liver Diseases
Boston, Massachusetts, United States  
November 9-13, 2012

The Liver Meeting® 2012
Published on Aug 22, 2012 by
Dr. Bezerra explains why the plenary, parallel, and poster sessions are the "essence" of The Liver Meeting® and how attendees can access those sessions through AASLD's LiverLearning® portal free of charge for one year.

AASLD - Liver Learning
"Liver Learning" @ the AASLD website includes meeting webcasts, video podcasts, abstracts....

The Liver Meeting® 2012
AASLD Website

No comments:

Post a Comment